A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Eli Lilly and Company
MOMA Therapeutics
Pheon Therapeutics
Kivu Bioscience Inc.
Boehringer Ingelheim
AbbVie
Eli Lilly and Company
Nammi Therapeutics Inc
Revolution Medicines, Inc.
Pfizer
PanTher Therapeutics
Alterome Therapeutics, Inc.
Arcus Biosciences, Inc.
Amgen
ImmunityBio, Inc.
Arbele Limited
RasCal Therapeutics, Inc.
Continuity Biosciences, LLC
ViroMissile, Inc.
Erasca, Inc.
ArriVent BioPharma, Inc.
Angiex, Inc.
Poseida Therapeutics, Inc.
MacroGenics
Revolution Medicines, Inc.
Boehringer Ingelheim
General Oncology, Inc.
SN BioScience
Cue Biopharma
Peptomyc S.L.
Eli Lilly and Company
TORL Biotherapeutics, LLC
Novartis
PAQ Therapeutics, Inc.
Legend Biotech USA Inc
Degron Therapeutics Co.
Bristol-Myers Squibb
Nihon Medi-Physics Co., Ltd.
Nuvation Bio Inc.
Actym Therapeutics, Inc.
Amgen
Chongqing Precision Biotech Co., Ltd
Sichuan Baili Pharmaceutical Co., Ltd.
HUYABIO International, LLC.
HUYABIO International, LLC.
Ikena Oncology
Sichuan Baili Pharmaceutical Co., Ltd.
MacroGenics